Decoy Therapeutics Inc.

DCOYSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1615219

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	$1.8M	$5.2M	$3.5M
Cost of Goods and Services Sold	—	—	—	—	—
Research and Development Expense	$7.2M	$15.8M	$8.5M	$6.9M	$4.0M
Operating Expenses	$12.9M	$31.8M	$14.7M	$13.0M	$11.7M
Operating Income (Loss)	-$12.9M	-$31.8M	-$12.8M	-$7.8M	-$8.3M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	—	—
Income Tax Expense (Benefit)	—	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$6.6M	$14.7M	$40.8M	$24.9M	$13.9M
Assets, Current	$6.5M	$14.5M	$30.2M	$15.8M	$4.7M
Cash and Cash Equivalents, at Carrying Value	$5.9M	$12.1M	$29.2M	$11.1M	$3.7M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	—	—
Inventory, Net	—	—	—	—	—
Liabilities	$1.3M	$4.3M	$2.1M	$2.8M	$3.3M
Liabilities, Current	—	—	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$12.8M	-$17.6M	-$10.2M	-$10.3M	-$11.6M
Net Cash Provided by (Used in) Investing Activities	—	-$1.5M	$0.00	-$2.6K	$5.6M
Net Cash Provided by (Used in) Financing Activities	$6.6M	$2.0M	$28.3M	$17.7M	$3.6M
Payments to Acquire Property, Plant, and Equipment	—	—	—	$2.6K	$0.00
Payments of Dividends	—	—	—	—	$133.6K
Payments for Repurchase of Equity	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)